期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

VD方案联合自体造血干细胞移植治疗难治性不分泌型多发性骨髓瘤一例并文献复习 被引量：2

原文传递
导出
摘要 目的观察硼替佐米＋地塞米松（VD）方案联合自体造血心田胞移植（ASCT）治疗一例难治性不分泌型多发性骨髓瘤（MM）患者的疗效。方法通过对1例难治性不分泌型MM患苦给予VD方案化疗4个周期，在疾病得到有效控制、临床体征改善后，进行ASCT（预处理方案为美法仑200mg／m^2），并对国内外相关文献复习.结果患者经过化疗达到接近完全缓解（nCR），之后联合ASCT后达到完全缓解（CR）。结论VD方案联合ASCT可明显改善难治性小分泌型MM患者的临床预后。
作者 冯术青 李晓宇 朱梦波 崔晓聪 杜晓梅 闫兴双 高峰
机构地区 唐山钢铁集团有限责任公司医院血液肿瘤科
出处 《白血病．淋巴瘤》 CAS 2011年第2期108-110,共3页 Journal of Leukemia & Lymphoma
关键词 造血干细胞移植 多发性骨髓瘤 药物疗法 联合
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献5

二级参考文献51

  • 1Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in muhiple myeloma. Intergroupe Francais du Myelome [see comments]. N Engl J Med, 1996, 335: 91-97. 被引量：1
  • 2Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 2003, 348: 1875-1883. 被引量：1
  • 3Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem -cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol, 2005, 23: 9227-9233. 被引量：1
  • 4Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood, 2005, 106: 3755- 3759. 被引量：1
  • 5Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol, 2006, 24: 929-936. 被引量：1
  • 6Moreau P, Faeon T, Attal M, et al. Comparison of 200 mg/m^2 melphalan and 8 Gy total body irradiation plus 140 mg/m^2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood, 2002, 99: 731-735. 被引量：1
  • 7Moreau P, Hullin C, Garban F, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma:final results of the Prospective and randomized IFM 99-04 protocol. Blood, 2006, 107: 397-403. 被引量：1
  • 8Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med, 2003, 349: 2495-2502. 被引量：1
  • 9Barlogie B, Tricot GJ, van Rhee F, et al. Long term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Hematol, 2006, 135: 158-164. 被引量：1
  • 10Barlogie B, Tricot G, Anaissie E, ct al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med, 2006, 354: 1021-1030. 被引量：1

共引文献38

同被引文献53

  • 1苗瑞新.造血干/祖细胞动员临床研究新进展[J].国际移植与血液净化杂志,2006,4(3):32-35. 被引量：2
  • 2Cavo M,Rajkumar SV,Palumbo A. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem celltransplantation[J].{H}Blood,2011,(23):6063-6073. 被引量：1
  • 3Koreth J,Cutler CS,Djulbegovic B. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:A systematic review and meta-analysis of randomized control ed trials[J].{H}Biology of Blood and Marrow Transplantation,2007,(02):183-196. 被引量：1
  • 4Lentzsch S,O'Sul ivan A,Kennedy RC. Combination of bendamustine,lenalidomide,and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective:results of phase 1/2 open-label,dose escalation study[J].{H}Blood,2012,(20):4608-4613. 被引量：1
  • 5Eom HS,Min CK,Cho BS. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem celltransplantation for multiple myeloma[J].{H}Japanese Journal of Clinical Oncology,2009,(07):449-455. 被引量：1
  • 6Rosi?ol L,Oriol A,Teruel AI. Superiority of bortezomib,thalidomide,and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma:a randomized phase 3 PETHEMA/GEM study[J].{H}Blood,2012,(08):1589-1596. 被引量：1
  • 7Mikhael JR,Reeder CB,Libby III EN. Results From the Phase II Dose Expansion of Cyclophosphamide, Carfilzomib, Thalidomide and Dexamethasone(CYCLONE)in Patients with Newly Diagnosed Multiple Myeloma[J].Blood(ASH Annual Meeting Abstracts),2012.445. 被引量：1
  • 8Roussel M,Moreau P,Huynh A. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem celltransplantation in patients with de novo multiple myeloma:a phase 2 study of the Intergroupe Francophone du Myelome (IFM)[J].{H}Blood,2010,(01):32-37. 被引量：1
  • 9Perrone CM,Ceccolini G,Lauta M. Superiority of Double over Single Autologous Stem-cellTransplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response:Final Analysis of"Bologna 96"Study[J].Blood(ASH Annual Meeting Abstracts),2007.730. 被引量：1
  • 10Martinez-Lopez J,Blade J,Mateos MV. Long-term prognostic significance of response in multiple myeloma after stem celltransplantation[J].{H}Blood,2011,(03):529-534. 被引量：1

引证文献2

二级引证文献19

白血病．淋巴瘤
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部